ARID1A and colorectal carcinoma: It is more likely that tumors with the A59T variant and no evidence of dMMR/MSI-H or other coalterations, such as ARID1A, POLE, etc., behave biologically and clinically as one would expect from the general pool of mutant KRAS CRC tumors (i.e., resistant to EGFR inhibition).